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Henry T. Greely*
Let me begin by briefly addressing the social, ethical, and legal
issues with respect to biobanks generally, and then the special
considerations, the special problems, that arise from biobanking
and particular human populations. It is important to remember that
for almost every purpose, and particularly for purposes involving
medical use, biobanks have to be more than just collections of
physical specimens. DNA is not very useful for medical purposes
unless you know something about the person's health history. You
cannot find the gene for blue eyes from DNA unless you know
whether people who gave you the DNA had blue eyes.
So, to be useful, biobanks really are more than just biological
banks. They are combinations of physical samples of DNA-
which may be tumor tissues or something else-plus medical
information about a person. I have tried calling them phenotype-
genotype resources, an extremely clunky term that has not caught
on, but it has the advantage of being accurate. They are resources
that have both physical samples of genetic material and have
information about each donor's phenotype; genotype is what your
genes say about you, and phenotype is your body as it exists. So a
biobank needs both phenotype information and genotype
information to be really useful.
Now, one important thing to know about these large genotype-
phenotype resources is that their value is promising but
speculative. No one really knows whether we are going to make
great discoveries as a result of having 200,000 samples of DNA
coupled with health information about people. It seems like a good
way forward, in part because the traditional way of doing genetic
research in health seems to have stalled to some extent. As we
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have gotten past the simple genetic diseases, the ones that are
caused by a single gene, the so-called simple Mendelian disorders,
we have discovered, first, that many of those simple Mendelian
disorders were not as simple as we thought and, second, that there
are known genetic connections to much more common and
significant diseases, but those connections are turning out to be
really hard to tease out.
We know that there are genetic connections to schizophrenia,
which affects one percent of the population,' to diabetes, which
affects six-to-eight percent of the population,2 to various cancers,
to high blood pressure,3 to Alzheimer's Disease,4 to lots of diseases
that affect lots of people. But finding out how the genes connect to
those diseases has turned out to be really hard, and it is hoped that
collecting huge amounts of data from large numbers of people will
give us a way to better make those connections. At least that is the
hope, and that hope may prove true.
There are two things we know for sure about such genotype-
phenotype resources though. The first is that they are really
expensive. The Iceland Project, if it ever actually happens in its
entirety, is likely to cost several billion dollars to create a
1. Julian Guthrie, A Family's Journey to Madness and Back: Son's
Schizophrenia Spurs Parents to Raise Millions for Research, San Fransisco
Chronicle, Sept. 7, 2004, at Al, available at 2004 WLNR 7643201; Common
Genetic Influence Found in Mental Illnesses-Schizophrenia, Genomics and
Genetics Weekly, Feb. 13, 2004, at 69, available at 2004 WLNR 936138;
Demosthenes A. Lorandos, Secrecy and Genetics in Adoption Law and Practice,
27 Loy. U. Chi. L.J. 277, 284 (1996); Lori Andrews and Erin Shaughnessy
Zuiker, Ethical, Legal, and Social Issues in Genetic Testing for Complex
Genetic Diseases, 37 Val. U. L. Rev. 793, 799 (2003).
2. Eric G. Stark, Diabetes Carries a Costly Toll, Sunday News, Lancaster,
PA, Aug. 1, 2004, at 1, available at 2004 WLNR 11488523; Andrienne Forman,
The Second National Conference on Diabesity in America, Nutrition Today,
Nov. 1, 2004, at 245, available at 2004 WLNR 15747171.
3. Chris Winkelman, Genomics: What Every Critical Care Nurse Needs to
Know About the Genetic Contribution to Critical Illness, 24 Critical Care Nurse
34, June 1, 2004, available at 2004 WLNR 5689392.
4. Laura McConnell et al., Genetic Testing and Alzheimer Disease:
Recommendations of the Stanford Program in Genomics, Ethics, and Society, 3
Genetic Testing 3-12 (May 1999); Laura McConnell, Barbara A. Koenig, Henry
T. Greely, & Thomas A. Raffin, Genetic Testing and Alzheimer Disease: Has
the Time Come?, 7 Nature Medicine 757-59 (July 1998).
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genotype-phenotype resource encompassing just 250,000 people.5
The U.K. is planning to sample 500,000 British citizens, subjects
of Her Majesty the Queen, and they are budgeting several billion
dollars for that project.6
Ironically, the genetic side is the cheap part; it is not that
expensive to get samples from people with a cheek swab or a blood
draw. The expense is attributable to getting good health
information, inputting it, and making sure that it is good
information. So, first, we know biobanking is going to be
expensive.7 Second, we know that it is going to have lots of tricky
ethical, social, and legal issues.
8
About eight years ago, Bartha Knoppers, Ken Kidd, and I were
at a meeting, I think in the suburban D.C. area when Bartha was
Chair of the Ethics Committee of the Human Genome
Organization, an international, non-profit, non-governmental
group. The Committee put together a set of principles to govern
research in human population genetics.9 I am afraid that I cannot
remember these principles now except that they all started with
"C" and that they were Bartha's Ten Commandments.' ° I do
remember at least five that are particularly important in this area:
5. Henry T. Greely, Iceland's Plan for Genomic Research: Facts and
Implications, 40 Jurimetrics J. 153 (2000).
6. Roger Brownsword, An Interest in Human Dignity as the Basis for
Genomics Torts, 42 Washburn L.J. 413 (2003).
7. Alice Hsieh, A Nation's Genes for A Cure to Cancer: Evolving Ethical,
Social and Legal Issues Regarding Population Genetic Databases, 37 Colum.
J.L. & Soc. Probs, 359, 360 (2004).
8. Id; J. V. McHale, Regulating Genetic Databases: Some Legal and
Ethical Issues, 12 Med. L. Rev. 70 (2004).
9. Meeting of the Human Genome Organization Ethical, Legal, and Social
Issues Committee (since renamed the HUGO Ethics Committee) at Bethesda,
Maryland, Oct. 14-15, 1995. I was not a member of that Committee but was
asked, along with Professor Kidd, to give a presentation to them on the Human
Genome Diversity Project. We stayed for the discussion of their proposed
statement on the ethics of genetics research, which became the Committee's
report to the HUGO Council entitled "Statement on Principled Conduct of
Genetics Research." That report can be found at http://www.gene.
ucl.ac.uk/hugo/conduct.htm. It was adopted by the HUGO Council on March
21, 1996, http://www.csu.edu.au/leaming/eubios/HUGO.htm1.
10. Statement On The Principled Conduct Of Genetics Research,
http://www.csu.edu.au/learning/eubios/HUGO.html
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consent, control, confidentiality, communication, and commerce."1
For each, biobanking adds new ethical, legal, and social
complications to the existing complexities of research.
First, with respect to consent, if you are going to try to get
health materials, health information, and physical genetic samples
from people, from a lot of people, that takes a lot of consent, and it
is very tempting to short-circuit that labor and time-intensive effort
to get people to say "yes." Iceland did that short-circuiting. The
Icelandic legislation does not require the consent of people to be in
the health data side of the private company's (deCODE)
database.12 And it is that failure of informed consent that has, in
part, kept that database tied up in public controversy and litigation
in Iceland. 13 More than five years after the passage of legislation
that authorized deCODE to set up that database, it still does not
exist.
Control, I think in some ways, is even more important. Control
over what uses biobank material can be put to is an important
concern for subjects, or at least it should be. I am happy to give
my samples and my health information for research on a wide
variety of medically related topics. And in traditional research,
someone would be interested in premature grey hair and come to
me and say, "Boy, do we need your sample." And I'd say, "Sure.
No problem." With biobanking, in part because it is so expensive,
nobody wants to create a set of 200,000 samples and information
just to look at one disease, even one affirmative, enhancing
condition like premature grey hair, no matter how important it is.
You want to be able to use it for everything in order to amortize
that several billion dollar cost.
So if I give a sample to be biobanked, I am giving it away not
just for the study of premature grey hair, but for the study of all
sorts of things, some of which I may not like. Personally, I would
not want my samples to be used for studies of, say, race and
intelligence, because I think that would likely be misused in bad
11. Id.
12. Greely, supra, note 5; Michael J. Smith, Population-Based Genetic
Studies: Informed Consent and Confidentiality, 18 Santa Clara Computer &
High Tech L.J. 57, 68 (2001).
13. Greely, supra note 5.
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ways. I might be reluctant to have my samples used for studies of
Irish heritage and alcoholism, two things that run in my family,
and, frankly, something that my year in New Orleans with Judge
Wisdom threatened greatly to exacerbate. (I should make clear, it
was a function of New Orleans, not of Judge Wisdom.) So, what
makes biobanking different is that you have this large resource to
be used for many purposes and, under most algorithms, when you
make the decision to be a participant, you no longer hold control
over what your samples are going to be used for.
Third is confidentiality, preventing unauthorized uses of
information that a patient or a subject handed over in confidence.
("Confidentiality" is a narrower term than "privacy," which can
include attempts by others to learn information that the individual
has not voluntarily handed over to someone, as well as more
fundamental issues of bodily autonomy, such as those involved in
reproductive decisions.) It is important for researchers to try to
keep identifying information as confidential as possible and, yet,
biobanking can make that difficult-particularly biobanks that
want to keep adding new information as it comes up, as is the case
in Iceland. If you are going to keep adding new medical
information, somebody or something has to know that Computer
File No. 1473892 is Hank Greely. Otherwise, when you get new
information on Hank Greely, you cannot add it to his file.
Well, once you have got that, once you no longer can
completely anonymize and break the link between the person's file
and the person, you have the potential for a variety of different
breaks of confidentiality-there is a chance of that information
getting out in one way or the other. In addition, because this is not
very well appreciated but very important, it must be emphasized
even anonymous data these days really is not very anonymous.
If you want to have good health information on somebody, for
good research purposes, you can take away their name, you can
take away their Social Security number, you can take away their
address, but you probably do not want to take away, for example,
where they were born, or when they were born, or their sex, their
race, and so forth. That can make a difference in some research.
So, I was born in Columbus, Ohio in 1952. Based on the size
of Columbus, Ohio at that time, my guess is there were seven
children born the day I was born. They would, most likely, have
2005]
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been four boys and three girls. One of the boys was probably
black; three of the boys were probably white. You look at my
birthplace and my date of birth, and you check the records of
Franklin County, Ohio, and you are down to only three people in
the world that I might be.
So that confidentiality, even with anonymous data, cannot be
guaranteed any more because a rich data set-and you want a rich
data set of health information for your scientific purposes-will
have information that somebody could use to track down and
identify a person relatively easily. The greater computerization of
data, the greater accessibility of data through the Internet, and the
genealogy folks, bless their hearts, are trying to get all sorts of
public records information onto the Internet as fast as possible, but
this only increases this issue. So, confidentiality is a real problem.
Fourth, the problem of communication. Let us say my DNA is
in a biobank and some researchers analyze it. They discover that I
have a mutation in the MLH1 gene that predisposes me to
hereditary colon cancer. This would be a really interesting piece of
information for me because people with this mutation are highly
likely to get colon cancer, but dying from colon cancer is fairly
preventable if you get regular checkups, regular colonoscopies, or
even have your colon taken out entirely. A colectomy is not a
great thing, but it is a lot better than dying of metastatic colon
cancer.
I would really like to know if I have a mutation in my MLH I
gene. But do the people running the biobank have an obligation to
tell me that? If they are watching 200,000 people, every time one
comes up with a health risk, do they have an obligation to go back
and report? Every time they discover a new health risk, do they
have to go back and look through the bank and say, "You know,
we never realized that this apoE-4 variant is not only associated
with high blood pressure and heart disease, but also with
Alzheimer's Disease, and now we know it. Should we go back and
tell all the people we know have apoE-4 alleles that they're at risk
for Alzheimer's Disease?" Good questions I think. I would love
to be the plaintiff's lawyer for the family of the person who died
with colon cancer when a biobank knew that he had the gene
mutation but did not tell him about it.
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The last issue is commerce. Because these biobanks are so
expensive, they are largely, except in the U.K., being funded or
supported with private money. People want to get a return on their
investments of several billion dollars, and that certainly is
understandable. Now, in traditional medicine and traditional
genetics disease research, I, a research subject, might be from a
family with a history of breast cancer. I would go to the researcher
because I would hope it is going to help me, or my family
members, my daughters, my granddaughters, and so forth.
In biobanking, we could be looking at anything. So, I give you
my DNA, you may use it to find things about diseases that I care
about a lot, or for diseases that I do not care about very much. You
are going to make millions of dollars out of it, or at least so you
hope. You are the researcher, with your stock options and your
Scientific Advisory Board memberships, and some people are
going to make a lot of money out of this. I am not getting anything
for it. I feel like a sucker. Commerce, commercial concerns, I
think, should be greater for subjects in a world of widespread
genotype-phenotype resources. So I think those are really big,
important issues with respect to these biobanks, and they're issues
that we don't have good answers for yet.
I want to really stress what Michael Malinowksi said, that we
mainly have questions. We do not have well-accepted answers, we
do not have answers that are written into law, or that even are
clearly understood and agreed upon by researchers, let alone by
research subjects. The potential here that I worry about is the
potential for subjects to feel they have been cheated, betrayed, or
lied to. The potential is, on a lesser level, a genetic Tuskegee.
The Tuskegee study, where African-American farm laborers
were watched but not treated for syphilis for over forty years by
the U.S. Government, was a horrific event. 14 Moreover, it has
augmented the distrust by African-Americans of medical research
and, in fact, even serves as a focus for concerns by African-
Americans about medical research. 1  Tuskegee has, at the very
14. See generally James H. Jones, Bad Blood; The Tuskagee Syphilis
Experiment (2d ed. Free Press 1993).
15. Dorothy E. Roberts, The Nature of Blacks' Skepticism About Genetic
Testing: Purpose, Voice, and Values Essay, 27 Seton Hall L. Rev. 971 (1997).
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least, contributed to the generally lower rate of participation in
medical research by African-Americans compared to European-
Americans.16  We do not want that in genetics, for African-
Americans, cystic fibrosis patients, or any other group. We do not
want people to feel cheated and betrayed. It is bad for the research
if people do not feel that they have been treated well by
researchers. And all of these issues with respect to biobanks have
the potential for leading to that kind of disillusionment and
unhappiness.
Let me talk now a little bit about populations. When I talk
about population research, I could mean two different things. One
possibility is to encompass entire populations. Iceland is
attempting to get all of its population to participate. Now, it has
been five years, and I think it is unlikely that DeCode will ever
achieve what the film clip that Professor Malinowski showed
implies already exists. Alternatively, population research can
focus on a particular disease among a particular population. Tay-
Sachs disease among Cajuns, alcoholism among the Irish,
schizophrenia among the Hopi, whatever it is, this approach looks
at genetic variation within a particular culturally defined
population. Researchers do that a lot because we know, from
epidemiology, that some populations have higher rates of certain
diseases than others. We do not know in advance whether the
cause is genetic, environmental, or a combination of the two, but
we know that disease rates differ some from population to
population.
It is often recounted that F. Scott Fitzgerald once said to Ernest
Hemingway, "The rich are different from you and me," and that
16. That African-Americans are less willing to participate in biomedical
research is widely believed and the reason has often been traced to distrust See,
e.g., Giselle Corbie-Smith, Stephen B. Thomas, Mark V. Williams, Sandra
Moody-Ayers, Attitudes and Beliefs of African-Americans Toward Participation
in Medical Research, 14 J. Gen. Int. Med. 537 (1999). But see David Wendler,
et. al., Are Ethnic Minorities Less Willing to Participate in Health Research?, 3-
PLOS-Medicine, No. 2, e 19 (Feb. 2006), available at
http://medicine.plosjoumals.org/perl serv/?request=-get-
document&doi=10.1371/journal.pmed.0030019 (arguing that the reason for
lower African-American participation in medical research is insufficient
outreach to African-American populations).
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Hemmingway replied, "Yes, they have more money."'17 If I say
"Population research is different from individual research," you
could say, "Yeah, there are more individuals involved." I do not
think that is right. I think population research is qualitatively
different because, when you do research concerning a population,
those results affect the entire population, including the people who
chose not to participate, or who were never asked whether they
wanted to participate. If you put out a research finding that says
the Irish have a particularly high rate of carrying an alcoholism
gene, that affects every person of Irish ancestry. If you put out
something that says the Hopi have a particularly high rate of
schizophrenia-please note, I am making up these examples, but if
that is what you say-that affects all the Hopi, those who
participated in the study and those who did not. Population
research has broader effects because it says something, not just
about the individual who participates or that individual's
immediate family, but about everybody who falls into that
culturally defined group.
In general, we like to think that people who might be
negatively affected by research have the right to decide whether
they want to participate in it or not. And that brings me to some of
the same five issues I discussed above, now played through in a
population context. First, consider consent. In addition to
requiring individual consent, when research is about a group,
should we require group consent? Now I have been out on one end
of this argument, arguing that when it is feasible, we should. That
is not a popular end, in part because it is often going to be very
hard to figure out what the group is, how you can get their consent,
17. This excellent repartee is apparently apocryphal. See the discussion by
Professor James West, a Fitzgerald scholar, in an on-line discussion of
Fitzgerald, http://www.washingtonpost.com/wp-dyn/content/discussion/2005/
08/26/DI2005082601396.html. Hemingway did include a version of the
exchange, between Fitzgerald and an unnamed third party, in his short story,
The Snows of Kilamanjaro, where the autobiographical narrator says:
The rich were dull and they drank too much or they played too much
backgammon. They were dull and they were repetitious. He
remembered poor Scott Fitzgerald and his romantic awe of them and
how he had started a story once that began, "The rich are different from
you and me." And how someone had said to Scott, "Yes, they have
more money."
See the discussion of this incident in John Updike, Poor Little Rich Boy, The
Guardian, June 21, 2003.
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or who speaks for them. But I think, when you can do it, you
should do it. Even when there is no organized group from which
to seek consent, in this kind of research you should always pay
attention to the group. Maybe you cannot get all Cajuns to agree
on anything. There is no Cajun government or organization that
speaks for all Cajuns, but you can talk to Cajun groups, you can
talk about the effects of the research on all Cajuns. You can give
talks in parishes up and down south Louisiana and get the Cajun
population at least to think about these implications.
Control in this context is, in some ways, even more important.
Some groups will be happy to participate in some research,
particularly research aimed at diseases that affect them. Giving
subjects some control over how their samples can be used can be
important. The late Ryk Ward, a genetic anthropologist, ran into
trouble a few years ago. He had collected samples from a tribe in
British Columbia to be used in disease-focused research-
arthritis.18  He ended up using the samples later in some
anthropological research, looking at connections between that tribe
and other tribes.' 9 The tribe found out and was really annoyed.
They said, "We didn't give it to you for that. We gave it to you to
find out about our diseases. We don't care whether you think we
came over the Bering Strait or not. That's not the kind of research
we want." And they felt unhappy with him-betrayed and
cheated.
Confidentiality is the third factor. Confidentiality in a group
context may sound kind of silly, but perhaps it is not. Do you have
to say, "We found a gene that correlates with alcoholism in the
Irish?" Could you say in Celtic populations, or in northern
European populations? Do you have to say that the schizophrenia
gene is from the Hopi? Could you say Puebloan peoples? Could
you say a tribe from southwest United States? Of course, every
time you fuzz the identity, you do lose something. Literature, the
scientific literature, is not as clear and concise. Somebody might
18. They Need Your DNA, New Scientist, Sept. 30, 2000, available at 2000
WLNR 17410; Kurt Kleiner, Blood Fued, New Scientist, Sept. 30, 2000,
available at 2000 WLNR 17453.
19. Ann Gibbons, The Peopling of the Americas, Science, Oct. 4, 1996,
1996 WLNR 3527432.
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try to repeat the schizophrenia research on the Hopi, not realizing
that you have already done it. But the Hopi might insist on it, or
the Irish might insist on it, or others might insist on it as a way of
protecting their reputations from your research.
Fourth, let us consider communication in the group research
context. Too often, scientists think that, when they have done
research with groups, communicating the results back to them
means sending them reprints of their articles-which the scientists
think are written in English, although real people do not think that
they are written in English. And some populations do not read
English. Communicating results back should often mean going
back in person, talking to people, telling them your results, giving
them a chance to ask questions, and explaining it in language they
understand. They should understand that the samples they gave
you and the interview they gave you three years ago did not just
disappear into a black hole; rather, it generated some results.
Maybe they are great, exciting, wonderful results. Ninety-nine
percent of the time they are negative or equivocal results, but you
have found out something and you have told them what it is. This
process of communication respects their participation.
Commerce, the last of these issues, also takes on a different
aspect with populations, particularly, though not exclusively, when
you are talking about populations that are not a majority and may
have been oppressed by the majority population. They say, "You
came, you took our land, you took our people, you took our
resources. Now, you're trying to take our genes. And you want to
make a lot of money out of it, and none of it is coming back to us."
This concept, I think, has been greatly exaggerated.
I do not think this happened at all in human genetics, in part
because I do not think any particular human gene-more
accurately, "allele"--found in any particular group has been all
that important. Groups do not have genes different from those of
other people, and they rarely even have variations that are not
found anyplace else. But a lot of people who have been exploited
in the past, who feel that they have been exploited, have real
concern that this is just another way of exploiting them. And so,
having some sort of sharing of financial gains is, I think, an
important way to try to assuage those fears to both be more fair
and to appear more fair.
2005]
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Now, like all of these concerns and possible solutions, the
solution is tricky as well. You cannot get research subjects by
promising them too much of a return. That is unfair inducement.
If groups think that their participation in research is like a lottery
ticket because of a three percent royalty, then you run the risk that
you are misrepresenting the real benefits to them by inducing them
to take part in research under false pretenses. They may believe
they are all going to be rich when, at least 99.9 times out of 100,
they will not be. You know that you will get only about sixty-
seven cents back on the dollar if you play the lottery long enough,
but people still buy lots of lottery tickets. Yet, to completely
ignore the one in a hundred possibility and to take from a group
without any possibility of a return also seems wrong to me.
I have given you far more questions, I think, than answers.
That is because we are at a point where this research has begun,
but it has not become common enough to create shared
expectations. We are the people, we are the generation that has
both the opportunity and the duty to create some settled
expectations, some rules, some guidelines, some standards, about
how people in biobanks and populations in biobanks should be
treated. We need to think that through and do a good job, because
how well the research subjects feel they have been treated is at
stake. In the long run, the willingness of them to participate in
research and to support research is at stake. This is an issue, not
just of ethics and for ethicists, but of science and for scientists.
[Vol. 66
